Flicker Fusion Test Research Articles

The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia

Objectives of this study were to investigate the effects of prolonged-release melatonin 2 mg (PRM) on sleep and subsequent daytime psychomotor performance in patients aged > or =55 years with primary insomnia, as defined by fourth revision of the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association. Patients (N = 40) were treated nightly single-blind with placebo (2 weeks), randomized double-blind to PRM or placebo (3 weeks) followed by withdrawal period (3 weeks). Sleep was assessed by polysomnography, all-night sleep electroencephalography spectral analysis and questionnaires. Psychomotor performance was assessed by the Leeds Psychomotor Test battery. By the end of the double-blind treatment, the PRM group had significantly shorter sleep onset latency (9 min; P = 0.02) compared with the placebo group and scored significantly better in the Critical Flicker Fusion Test (P = 0.008) without negatively affecting sleep structure and architecture. Half of the patients reported substantial improvement in sleep quality at home with PRM compared with 15% with placebo (P = 0.018). No rebound effects were observed during withdrawal. In conclusion, nightly treatment with PRM effectively induced sleep and improved perceived quality of sleep in patients with primary insomnia aged > or =55 years. Daytime psychomotor performance was not impaired and was consistently better with PRM compared with placebo. PRM was well tolerated with no evidence of rebound effects.

Itraconazole, a potent inhibitor of P‐glycoprotein, moderately increases plasma concentrations of oral morphine

Individual variation in opioid response is considerable, partly due to pharmacokinetic factors. Transporter proteins are becoming increasingly interesting also in the pharmacokinetics of opioids. The efflux transporter P-glycoprotein can affect gastrointestinal absorption and tissue distribution, particularly brain access of many opioids. The aim of this study was to evaluate whether itraconazole, which is a potent inhibitor of P-glycoprotein and CYP3A4, would change the pharmacokinetics or the pharmacodynamics of oral morphine. Twelve healthy male volunteers ingested, in a randomized crossover study, once daily 200 mg itraconazole or placebo for 4 days. On day 4, 1 h after the last pre-treatment dose, the subjects ingested 0.3 mg/kg morphine. Blood samples for the determination of plasma morphine, morphine-3-glucuronide (M3G), morphine-6-glucuronide (M6G) and itraconazole concentrations were drawn up to 48 h after morphine ingestion. Pharmacodynamic effects were evaluated using a questionnaire, visual analogue scales, a reaction time test, the Digit Symbol Substitution Test and the Critical Flicker Fusion Test. Itraconazole increased the mean area under the plasma concentration-time curve [AUC (0-9)] of morphine by 29% (P=0.002), its AUC (0-48) by 22% (P=0.013) and its peak plasma concentration by 28% (P=0.035). Itraconazole did not significantly affect the pharmacokinetic variables of M3G or M6G or the pharmacodynamic effects of morphine. Itraconazole moderately increases plasma concentrations of oral morphine, probably by enhancing its absorption by inhibiting intestinal wall P-glycoprotein. A possible improvement of morphine penetration to the brain could not be observed.

The Immediate and Delayed Effects of Acute Exercise on Low- and High-level Processing Tasks

Acute bouts of moderate-level, steady-state aerobic exercise facilitate select cognitive processes. Response speed and response accuracy during discrimination tasks that require low-level cognitive demand have been found to be facilitated both during and immediately following exercise. It is unclear, however, how high-level executive functions (EF), which are central to working memory and goal-directed actions, are affected during and following a bout of exercise. Some studies report interference of EF processing during exercise while other studies report facilitation of EF processing following exercise. PURPOSE: To examine the immediate and delayed effects of a single bout of aerobic exercise on a task requiring low-level cognitive demand and on a task requiring highlevel cognitive demand. METHODS: Nineteen young adults (8 males, 11 females; mean age=21 years, s.d.=1.68) performed brief tests of sensory discrimination (Critical Flicker Fusion (CFF) test) and EF (modified Paced Auditory Serial Addition Task (PASAT)) prior to exercise, 5 times during a 40-min period of ergometer cycling at 90% ventilatory threshold, and 3 times during a 30-min post-exercise period. In a separate session, each participant completed a control condition in which the same sequence of tests was administered while the participant was seated on the ergometer but no exercise was performed. RESULTS: Within-subject ANOVAs were performed separately on CFF and PASAT scores, which compared performance during exercise and non-exercise conditions at 9 time points. Analyses of CFF scores revealed a significant interaction between test condition and time (F=5.97, p<0.001). Post-hoc analyses revealed that CFF thresholds increased only during exercise and that change was linearly related to exercise duration. Analyses of PASAT scores did not yield any statistically significant main effects or interactions. CONCLUSIONS: Exercise-induced physiological arousal facilitates informationprocessing during mental tasks that require low-level cognitive processing but only during exercise. Arousal did not influence young adults' performance on a working-memory task that purportedly requires high-level mental processing either during or following exercise.

The effect of modafinil following acute CPAP withdrawal: a preliminary study

Daytime symptoms resulting from obstructive sleep apnea (OSA) include impaired neurobehavioural performance and increased sleepiness. Continuous positive airway pressure (CPAP) reduces these symptoms. However, even compliant users may temporarily withdraw from CPAP treatment resulting in an immediate return of OSA. It has been hypothesised that these treatment "holidays" may be associated with neurobehavioural decline. Acute administration of a wakefulness promoter during such treatment "holidays" may help maintain neurobehavioural functioning. We examined the effects of 200 mg modafinil on neurobehavioural performance in a placebo-controlled crossover trial including N = 12 OSA patients acutely removed from CPAP. Sleep-wake activity was assessed for four consecutive days on CPAP and one night off CPAP using actigraphy. During the night off, CPAP patients wore a single channel nasal airflow diagnostic device. On the morning after CPAP withdrawal, patients reported to the laboratory and were administered either modafinil (200 mg) or placebo. At 2 h post-administration, patients completed a single simulated drive of approximately 30 min with simultaneous administration of a divided attention task (STISIMtrade mark), critical flicker fusion (CFF) test and subjective sleepiness scales. After a 14-day washout, participants repeated the protocol. CPAP withdrawal was associated with a worsening of sleep efficiency and the movement and fragmentation index (MFI), compared to the on-CPAP nights (all p < or = 0.02). Modafinil did not result in a superior driving simulator performance or CFF responses the morning after CPAP withdrawal but did result in better subjective sleepiness (both p < or = 0.04) compared to placebo. These data do not support the use of modafinil for the maintenance of daytime functioning in patients with OSA who are acutely withdrawn from CPAP.

Maintenance time of sedative effects after an intravenous infusion of diazepam: A guide for endoscopy using diazepam

To examine whether the sedative effects assessed by psychomotor tests would depend on the cytochrome P450 (CYP) 2C19 genotypes after an infusion regimen of diazepam commonly used for gastrointestinal endoscopy in Japan. Fifteen healthy Japanese volunteers consisting of three different CYP2C19 genotype groups underwent a critical flicker fusion test, an eye movement analysis and a postural sway test as a test for physical sedative effects, and a visual analog scale (VAS) symptom assessment method as a test for mental sedative effects during the 336 h period after the intravenous infusion of diazepam (5 mg). The physical sedative effects assessed by the critical flicker test continued for 1 h (t values of 5 min, 30 min and 60 min later: 4.35, 5.00 and 3.19, respectively) and those by the moving radial area of a postural sway test continued for 3 h (t values of 5 h, 30 h, 60 min and 3 h later: -4.05, -3.42, -2.17 and -2.58, respectively), which changed significantly compared with the baseline level before infusion (P<0.05). On the other hand, the mental sedative effects by the VAS method improved within 1 h. The CYP2C19 genotype-dependent differences in the postinfusion sedative effects were not observed in any of the four psychomotor function tests. With the psychomotor tests, the objective sedative effects of diazepam continued for 1 h to 3 h irrespective of CYP2C19 genotype status and the subjective sedative symptoms improved within 1 h. Up to 3 h of clinical care appears to be required after the infusion of diazepam, although patients feel subjectively improved.

Acute effects of zolpidem on daytime alertness, psychomotor and physical performance

In a double-blind cross-over study, seven athletes received zolpidem (10 mg) or placebo in two sessions over two nights. Residual effects on subsequent daytime functions were evaluated objectively by measuring psychomotor and physical performance using a combined test of finger dexterity, a simple discriminatory reaction test, critical flicker fusion test (CFF), vertical jump, and 50-m sprint, as well as subjectively, by visual analog scales. Zolpidem shortened self-estimated sleep latency and increased total sleep at nighttime. There was no change in alertness and fatigue scales on the following day in the zolpidem session, but realm of daytime well-being was slightly worsened. The CFF test showed significantly better results in the zolpidem group than in the placebo group. Zolpidem did not have effects in athletic evaluation. Zolpidem has a hypnotic activity without disturbing psychomotor and physical performance on the following day when given to healthy adults, suggesting zolpidem may be used in healthy athletes to adjust their extrinsic sleep disturbances and their consecutive psychomotor and physical impairments.

Different effects of light food on pharmacokinetics and pharmacodynamics of three benzodiazepines, quazepam, nitrazepam and diazepam

Quazepam, nitrazepam and diazepam are administered under fed or fasted conditions for insomnia or anxiety disorder. Light bedtime food may have clinically relevant effects on the plasma levels of those drugs and hence on psychomotor performance. This study assessed the effect of light food on the pharmacokinetics and pharmacodynamics of these drugs. Twenty-one eligible subjects were randomized to one of three groups of seven subjects: quazepam 20 mg, diazepam 5 mg or nitrazepam 5 mg. Each healthy subject took a single oral dose of the assigned drug after overnight fasting and after light food, on a separate occasion. Blood samples were collected until 72 h after dosing. The plasma samples were assayed using high-pressure liquid chromatography with spectrophotometric detection. Reaction time, critical flicker fusion test and visual analogue scales were conducted. The peak plasma concentration (C(max)) and area under the concentration-time curve (AUC) of quazepam with light food were 1.2-fold [90% confidence interval (CI): 1.1-1.5; P < 0.05] and 1.5-fold (90% CI: 1.3-1.9; P < 0.05) higher than that without light food, respectively. For nitrazepam and diazepam, the time to peak was delayed about 1 h in fed condition (P > 0.05). However it had no effect on their C(max) and AUC. Reaction time of quazepam with light food was prolonged at 4 and 6 h after dosing and its area under the effect-time curve from 0 to 10 h was increased (P < 0.05). Light food increased the bioavailability of quazepam and affected psychomotor performance. Light food delayed T(max) of nitrazepam and diazepam but had no effect on C(max) and AUC.

Comparison of the effects of a 24‐hour nicotine patch and a 16‐hour nicotine patch on smoking urges and sleep

This randomized, open-label, crossover study was conducted to compare the effects of a 24-hr nicotine patch and a 16-hr nicotine patch on morning smoking urges and sleep quality of dependent smokers during a short period of cigarette abstinence. A total of 20 smokers (9 women and 11 men) smoking at least 20 cigarettes/day completed the two smoke-free study periods. For each period, cigarette abstinence started on the first evening and a nicotine patch was applied the next morning (for 16 or 24 hr), after baseline measures; a second patch was applied the next morning, 1 hr before the end of the experimental period. Smoking urges, mood and behavior self-reports, psychomotor performance, and polysomnographic recordings were compared between the two types of nicotine patch according to changes from baseline. Both patches decreased morning smoking urges, although results were significantly superior for the 24-hr patch. Furthermore, the 24-hr patch was more effective than the 16-hr patch in reducing the positive reinforcing dimension of smoking urges. Regarding polysomnographic recordings, the proportion of slow wave sleep was significantly increased from baseline with the 24-hr patch compared with the 16-hr patch. As for psychomotor performance measured through the critical flicker fusion test, significant improvement in morning alertness was observed in the 24-hr patch group. In conclusion, the 24-hr nicotine patch formulation is more effective than the 16-hr formulation in alleviating morning smoking urges and more specifically the positive reinforcing factor. The present findings do not support the idea that nicotine delivery during bedtime might disturb sleep, but rather it improves restorative sleep and postwaking arousal.

Daytime variation in performance and tiredness/sleepiness ratings in patients with insomnia, narcolepsy, sleep apnea and normal controls

Daytime tiredness or sleepiness and deficits in cognitive performance are common complaints in sleep disordered patients. Till now there are few studies comparing patients from different diagnostic groups of sleep disorders in the same experimental protocol. We studied the time course of cognitive functions and subjective alertness in a parallel group design with four groups of patients [narcolepsy, untreated or treated obstructive sleep apnea (OSA), or psychophysiological insomnia] and a control group of subjects without sleep complaints. Each group consisted of 10 subjects, matched for age and gender. After a night with polysomnography, subjects were studied for 10 h from 08:00 hours to 18:00 hours at 20 min intervals under standardized environmental conditions. Four psychological tests were applied, (1) a critical flicker fusion (CFF) test to measure optical fusion threshold (alertness); (2) a paper-and-pencil visual line tracking test (selective attention); (3) a visual analog scale (VAS) for tiredness/sleepiness; and (4) the Tiredness Symptoms Scale (TSS), a 14 items check list. Each test session lasted for 8 min, followed by a 12 min pause. The level and time course of cognitive performance and self-rating data were analysed with hierarchical linear mixed effects models. Cognitive tests showed decrements in alertness and selective attention in untreated patients with insomnia, narcolepsy, and sleep apnea. Narcoleptic patients and untreated OSA had a lower CFF threshold than controls, and for narcoleptic patients the time course differed from that of all other groups. In the visual tracking test the performance of all groups of patients was worse compared with normal controls. Self-rated tiredness/sleepiness was significantly more pronounced in the three groups of untreated patients than in control subjects.

Influence of Exercise Duration and Hydration Status on Cognitive Function During Prolonged Cycling Exercise

The purpose of the present study was to examine the influence of submaximal aerobic exercise duration on simple and complex cognitive performance. Eight well-trained male subjects agreed to participate in this study (trial group). A control group of eight regularly trained male subjects was included for comparative purposes. For the trial group, the experiment involved a critical flicker fusion test (CFF) and a map recognition task performed before, every 20 min during, and immediately after, a 3-h cycling task at an intensity corresponding to approximately 60 % of VO2max. Data were obtained over two experimental sessions with fluid ingestion (F) or no fluid (NF) ingestion. For the control group the experiment was the same but without exercise and fluid ingestion. In the trial group, a significant effect of hydration status was observed on physiological parameters (p <0.05). No effect was found on cognitive performance. A significant decrease in CFF performance was observed after 120 min of exercise when compared with the first 20 min (respectively for CFFmdi: 2.6 vs. 3.8 Hz), irrespective of experimental condition. A significant improvement in speed of response (respectively: 3291 vs. 3062 msec for 20 and 120 min, respectively) and a decrease in error number (21.5 % vs. 6.0 % for 20 and 120 min, respectively) during the map recognition task were recorded between 80 min and 120 min when compared with the first 20 min of exercise. After 120 min the number of recorded errors was significantly greater indicating a shift in the accuracy-speed trade-off (6.0 % vs. 14.1 % for 120 and 180 min, respectively). These results provide some evidence for exercise-induced facilitation of cognitive function. However this positive effect disappears during prolonged exercise--as evidenced within our study by an increase in errors during the complex task and an alteration in perceptual response (i.e. the appearance of symptoms of central fatigue).

Facilitating effects of exercise on information processing

The aim of this study was to examine the facilitating effects of moderate physical exercise on the reaction process to gain a better understanding of the interaction between physiological and cognitive processes. Sixteen participants with specific expertise in decision-making sports performed a double task consisting of choice reaction time while cycling. Signal quality, stimulus–response compatibility and time uncertainty were manipulated. Participants were tested at rest and while cycling at 20% and at 50% of their maximal aerobic power. A mood assessment questionnaire and a critical flicker fusion test were administered before and after the choice reaction time task. The results showed that moderate-intensity exercise (50% maximal aerobic power) improves cognitive performance and that low-intensity exercise (20% maximal aerobic power) enables participants to compensate the negative dual-task effect.

Influence of physical exercise on perceptual response in aerobically trained subjects.

A significant effect of fatigue induced byphysical exercise leading to exhaustion was observed for 6 male triathletes using some specific analysis of the critical flicker fusion test.

May open angle glaucomatous disease (OAGD) be considered a neuro-ophthalmological entity?

Open-angle glaucomatous disease (OAGD)-type field loss may run in families with optic neuropathy, ganglion cell damage, and normal hydrodynamics. Recently, patients have been observed with moderately elevated intraocular pressure (IOP) and an absence of functional defects, except for disturbed foveal flicker fusion for the descending green mode, characteristic of a retinal magnoganglion cell impairment. Individuals who received no IOP-lowering treatment developed field defects later on, while those with normal foveal flicker fusion (FFF) tests for the descending green mode did not develop field changes, even without any IOP-lowering treatment. Histopathology of the complete optic pathway of advanced OAGD revealed pronounced but not total retinal ganglion cell loss. At the level of the simple ascending atrophic optic nerve, however, axons were observed with preserved myelin sheaths, proof that not all ganglion cells were lost, whereas the primary cause of total ascending optic atrophy can only be explained in OAGD by transsection of laminar optic nerve axons, due to impaired capillary output. Thus, changes in FFF frequencies appear to be the earliest functional hallmark in OAGD, while ophthalmoscopy under red-free light reveals loss of peripapillary axons as the first anatomic hallmark of OAGD optic neuropathy. Neuroprotective treatment has been reported to be beneficial. Faulty control of apoptosis (susceptibility factor) in some retinal ganglion cells before clinical symptoms develop may be the cause. The loss of ganglion cells occurs more rapidly in the presence of a relatively high IOP. Ultrastructural changes in guinea pig optic nerves have been reported after the experimental acute increase of IOP. In order to determine if the damage to some ganglion cells was due to the direct effect of the increased IOP or to a vascular stealing phenomenon, we repeated the experiments in birds (chickens) of which it is known that there is no vascular supply to the retinal ganglion cells. Progressively elevated IOP of different duration resulted in the appearance of an apoptotic look of some ganglion cells; when the duration of IOP elevation was longer, more cells were damaged. Additionally, a necrotic look appeared, while axons at the laminar level were rather mildly affected. Therefore, a different sensitivity of ganglion cells to the direct mechanical effect of IOP elevation appears to be likely. Besides the impairment of the choroidoscleral outflow damaging the axons, a more seriously damaging effect of raised IOP to some ganglion cells has to be considered in humans expressing the apoptotic p 53 gene before clinical symptoms develop.The ascending mode may be preponderant, acting simultaneously with the descending mode, but it must be emphasized that primary impairment of some retinal ganglion cells may be most probable.

Time-of-day variations of indicators of attention: performance, physiologic parameters, and self-assessment of sleepiness

Background: A study was performed to analyze time-of-day variations of different indicators of attention and their interrelations. Methods: After a sufficiently long all-night sleep 12 healthy non–sleep-deprived subjects ran through a test battery (Stanford Sleepiness Scale, Visual Analogue Scale, Critical Flicker Fusion Test [CFF], Visualization Test, Number Facility Test, Reaction Time, Pupillometry, and modified Multiple Sleep Latency Test) every 2 hours from 7:00 am until 11:00 pm. Time-of-day variations were tested nonparametrically with Friedman’s test for repeated measurements. Principal component factor analysis (of individually standardized values) was used to identify variable complexes with the same pattern of time-of-day variation. Results: Statistically significant time-of-day variations were found for all variables, except for Fusion Frequency in CFF and Reaction Time. In factor analysis the physiologic parameters (pupillometric variables and sleep latencies) load on one factor, whereas the self-assessment scales, the Visualization Test, Number Facilty Test, and CFF load on the second factor. The variables that load primarily on factor 1 show peak levels of alertness immediately after getting up (at 7:00 am) and again at 9:00 pm. Those variables that load primarily on factor 2 indicate a peak level of alertness around noon (11:00 am–3:00 pm). Conclusions: Different aspects of attention follow different time-of-day variations. It is discussed, that these findings can be attributed to underlying circadian and homeostatic factors.

Clinical uses of alpha2 -adrenergic agonists.

Clinical uses of alpha2 -adrenergic agonists.

The influence of established and new antiepileptic drugs on visual perception

In this study, we investigated visual performance under chronic antiepileptic drug treatment. Patients were under carbamazepine (CBZ) (n = 18), valproic acid (VPA) (n = 9), CBZ and vigabatrin (VGB) (n = 4), CBZ and gabapentin (GBP) (n = 8), and under CBZ and topiramate (TPR) (n = 6), respectively. Seven untreated patients with epilepsy and 42 healthy volunteers served as controls. The test battery comprised the Lanthony-D15-désaturé colour perception test, increment, postadaptation and transient tritanopia (TT) threshold measurements, visual perception threshold assessments for monochromatic and chromatic gratings and gaussian dots, and critical flicker fusion (CFF) tests. No differences were seen between naive patients and healthy controls. Patients under drug treatment always showed alterations of visual perception. Postadaptation and TT thresholds were altered under each drug regimen after short delays between switching off the adaptation light and switching on the blue test light. Threshold elevations were maximum under the combination of CBZ and TPR and lowest under CBZ and GBP. Consistent impairment of the CFF was seen under combined CBZ and TPR whereas VPA as well as combined CBZ and VGB led to ameliorations the mechanisms of which are discussed. The other tests were less sensitive. In conclusion, alterations of visual function were apparent under chronic antiepileptic drug treatment both with established and new agents. However, it may be difficult to distinguish between effects based on specific modes of action and nonspecific retino- and neurotoxicity.

Concentrations and Effects of Oral Midazolam are Greatly Reduced in Patients Treated with Carbamazepine or Phenytoin

Midazolam is a short-acting benzodiazepine which is used as an oral hypnotic agent in several countries. We studied the pharmacokinetic and pharmacodynamic aspects of an oral 15-mg dose of midazolam in 6 patients with epilepsy who are also taking carbamazepine (CBZ) or phenytoin (PHT). We compared results with those obtained in 7 noninduced control subjects. Plasma concentrations and effects of midazolam were measured for 10 h. In patients with epilepsy, the area under the plasma concentration-time curve (AUC) of midazolam (mean +/- SEM) was only 5.7% (0.60 +/- 0.16 vs. 10.5 +/- 0.6 microgram x min/ml), and the peak midazolam concentration was 7.4% (5.2 +/- 1.2 vs. 70.4 +/- 9.0 ng/ml) of its value in control subjects (p < 0.001). The elimination half-life (t l/2) of midazolam was 1.3 +/- 0.2 h in patients and 3.1 +/- 0.1 h in controls (p < 0.001). The low plasma midazolam concentrations in the patient group were associated with reduced pharmacodynamic effects as compared with control subjects [e.g., the Critical Flicker Fusion Test (CFFT), p < 0.05]. Induction of CYP3A (cytochrome P-450IIIA) enzymes by CBZ and PHT is the most likely explanation of the great difference in the pharmacokinetic and pharmacodynamic profiles of oral midazolam in the two groups.

True patient‐controlled sedation

A modified patient-controlled analgesia pump provided doses of propofol 3 mg or midazolam 0.1 mg in 0.3 ml, over 5.4 s, with no lockout, during transvaginal oocyte retrieval. Alfentanil 0.2 mg was administered at three points during the procedure, and on request. Patients were randomly assigned to receive either propofol (25 patients) or midazolam (22 patients). The mean age, weight, duration of procedure and dose of alfentanil were similar in both groups. Onset of sedation with propofol or midazolam took 70.6 (SD 22.4) and 106.3 (50.7) s respectively. Mean doses over the first 5 min were midazolam 2.7 (1.2) mg, and propofol 54 (18) mg. Thereafter requirements decreased: midazolam 0.065 (0.065) mg.min-1, propofol 2.1 (1.3) mg.min-1. All patients successfully completed the procedure; none required additional sedation. P-deletion, reaction time, and critical flicker fusion tests revealed similar depression in both groups immediately postoperatively. After 30 min the p-deletion and critical flicker fusion scores were still impaired in the midazolam, but not in the propofol, group.

Assessment of changes in psychomotor performance of elderly subjects.

1. The repeatability of a computerised psychomotor test battery on a day-to-day and week-to-week basis was assessed by determining its test-retest reliability and variations in group-means and intraindividual psychomotor performance scores of elderly people. 2. Psychomotor performance was assessed in 50 well-screened elderly subjects (21 males, 29 females; mean age 70.4 +/- 5.0 (s.d.) years) on 5 consecutive days and over 4 weeks in standardised test conditions. 3. The psychomotor test battery consisted of computerised versions of symbol digit substitution test (SDST), continuous attention test (CAT), choice reaction time (CRT), critical flicker fusion test (CFFT), cognitive flexibility test (FLEX), paired word association test (PWAT) and inspection time (INSP). 4. Main outcome measures were test-retest reliability, group variability and intraindividual variability. 5. There was no significant variation in group-means for all components of the test battery over 5 days or 4 weeks on two way analysis of variance. The intraindividual coefficient of variation was low for SDST, CRT, CFFT, FLEX, PWAT and INSP during the period of assessment. Test retest reliability was greater than 0.8 for SDST, CAT, CRT and PWAT. 6. Tests in the Automated Psychomotor Test Battery are reliable and repeatable measures of psychomotor performance on a day-to-day and week-to-week basis.

Exercise Alters the Pharmacokinetics of Midazolam

STROMBERG, C.; VANAKOSKI, J.; OLKKOLA, K. T.; LINDQVIST, A.; SEPPALA, T.; LAITINEN, L. A. Author Information